(FILE 'HOME' ENTERED AT 11:18:14 ON 09 SEP 2004)

```
FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
     AT 11:18:23 ON 09 SEP 2004
L1
          27151 S URINARY INCONTINENCE
L2
           1965 S (URETHRA? MUSCLE) OR (SPHINCTER MUSCLE)
             56 S L1 (L) L2
L3
L4
             43 DUP REM L3 (13 DUPLICATES REMOVED)
L5
             27 S L4 AND PY<=1998
L6
             27 SORT L5 PY
L7
        3691105 S INJECT? OR INTRODUC? OR IMPLANT? OR TRANSPLANT?
L8
              7 S L1 (L) L2 (L) L7
T.9
              5 DUP REM L8 (2 DUPLICATES REMOVED)
L10
              0 S L4 AND (GENE THERAPY)
             38 S L1 AND (GENE THERAPY)
L11
L12
             27 DUP REM L11 (11 DUPLICATES REMOVED)
L13
              2 S L12 AND PY<=1998
                E COLEMAN MICHAEL?/AU
                E CHANCELLOR MICHAEL?/AU
L14
             87 S E2
L15
             13 S L1 AND L14
L16
             11 DUP REM L15 (2 DUPLICATES REMOVED)
=> d an ti so au ab pi 116 1 3 7 8
```

- L16 ANSWER 1 OF 11 MEDLINE on STN
- AN 2004179241 MEDLINE
- TI Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency.
- SO Urology, (2004 Apr) 63 (4) 780-5. Journal code: 0366151. ISSN: 1527-9995.
- AU Chermansky Christopher J; Tarin Tatum; Kwon Dong-Duek; Jankowski Ronald J; Cannon Tracy W; de Groat William C; Huard Johnny; Chancellor Michael B
- AB OBJECTIVES: To determine whether allogenic muscle-derived cells (MDCs) could restore sphincter function in rats with intrinsic sphincter deficiency (ISD). ISD denotes a malfunction of the urethral sphincter. METHODS: ISD was produced in 25 adult female Sprague-Dawley rats by cauterizing tissues lateral to the mid-urethra. One week after cauterization, $1.5 \times 10(6)$ MDCs, genetically engineered for beta-galactosidase expression, was injected into the mid-urethra in 16 rats. Another 9 rats were injected with Hanks' balanced salt solution after cauterization. As a control, 9 normal rats underwent a sham operation. Sphincter function was studied using the vertical tilt table/intravesical pressure clamp technique to measure leak point pressures (LPPs). The fate of the MDCs was assessed using LacZ staining. RESULTS: The injection of MDCs increased the LPP without affecting bladder function. The mean LPP of the control rats 2, 4, and 6 weeks after the sham operation was 49.8 + -1.3, 51.2 + -1.5, and 51.6 + -2.0 cm H2O, respectively. The mean LPP of the rats 2, 4, and 6 weeks after cauterization and Hanks' balanced salt solution injection was 17.2 +/-1.4, 26.9 +/- 1.9, and 25.5 +/- 1.3 cm H2O, respectively. The mean LPP of the rats 2, 4, and 6 weeks after cauterization and MDC injection was 38.2 +/- 2.2, 43.1 +/- 2.6, and 51.5 +/- 0.9 cm H2O, respectively. LacZ staining confirmed that MDC had integrated within the striated muscle layer of the cauterized urethra. CONCLUSIONS: The injection of intraurethral MDCs improved sphincter function in rats with ISD and may provide an attractive alternative to current treatments.
- L16 ANSWER 3 OF 11 MEDLINE on STN
- AN 2003546645 MEDLINE
- TI Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra.
- SO Urology, (2003 Nov) 62 (5) 958-63. Journal code: 0366151. ISSN: 1527-9995.
- AU Cannon Tracy W; Lee Ji Youl; Somogyi George; Pruchnic Ryan; Smith Christopher P; Huard Johnny; Chancellor Michael B

OBJECTIVES: To study the physiologic outcome of allogenic transplant of muscle-derived progenitor cells (MDPCs) in the denervated female rat urethra. METHODS: MDPCs were isolated from muscle biopsies of normal 6-week-old Sprague-Dawley rats and purified using the preplate technique. Sciatic nerve-transected rats were used as a model of stress urinary incontinence. The experimental group was divided into three subgroups: control, denervated plus 20 microL saline injection, and denervated plus allogenic MDPCs (1 to 1.5 \times 10(6) cells) injection. Two weeks after injection, urethral muscle strips were prepared and underwent electrical field stimulation. The pharmacologic effects of d-tubocurare, phentolamine, and tetrodotoxin on the urethral strips were assessed by contractions induced by electrical field stimulation. The urethral tissues also underwent immunohistochemical staining for fast myosin heavy chain and CD4-activated lymphocytes. RESULTS: Urethral denervation resulted in a significant decrease of the maximal fast-twitch muscle contraction amplitude to only 8.77% of the normal urethra and partial impairment of smooth muscle contractility. Injection of MDPCs into the denervated sphincter significantly improved the fast-twitch muscle contraction amplitude to 87.02% of normal animals. Immunohistochemistry revealed a large amount of new skeletal muscle fiber formation at the injection site of the urethra with minimal inflammation. CD4 staining showed minimal lymphocyte infiltration around the MDPC injection sites. CONCLUSIONS: Urethral denervation resulted in near-total abolishment of the skeletal muscle and partial impairment of smooth muscle contractility. Allogenic MDPCs survived 2 weeks in sciatic nerve-transected urethra with minimal inflammation. This is the first report of the restoration of deficient urethral sphincter function through muscle-derived progenitor cell tissue engineering. MDPC-mediated cellular urethral myoplasty warrants additional investigation as a new method to treat stress urinary incontinence.

ANSWER 7 OF 11 L16 MEDLINE on STN

DUPLICATE 2

2002636392

MEDLINE

- Current and future pharmacological treatment for overactive bladder. TΙ
- SO Journal of urology, (2002 Nov) 168 (5) 1897-913. Ref: 176 Journal code: 0376374. ISSN: 0022-5347.
- ΑIJ Yoshimura Naoki; Chancellor Michael B
- AΒ PURPOSE: Urinary incontinence and overactive bladder are important and common conditions that have received little general medical attention. We reviewed the magnitude and impact of these conditions, and discuss pharmacotherapy as well as new drugs under investigation. MATERIALS AND METHODS: The main emphasis of this review is pharmacological therapy for the bladder. We discuss currently available agents, drugs under development and pharmacological targets that would be suitable targets for treating overactive bladder. Drugs such as duloxetine that target not bladder smooth muscle, but rather central nervous system control of the micturition reflex are undergoing clinical trials. We also discuss intravesical therapy and alternative drug delivery methods, such as intravesical capsaicin and botulinum toxin, with special emphasis on approaches to modulate bladder afferent nerve function for preventing overactive bladder. RESULTS: There are many advantages to advanced drug delivery systems, including long-term therapeutic efficacy, decreased side effects and improved patient compliance. Future speculation such as gene therapy holds great promise for overactive bladder because it is possible to access all genitourinary organs via endoscopy and other minimally invasive techniques that are ideally suited for gene therapy. CONCLUSIONS: Traditional anticholinergic therapies are limited in their effectiveness. There is great hope for future research regarding voiding dysfunction and urinary incontinence through a focus on afferent nerve intervention for preventing overactive bladder.

L16 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:780710 CAPLUS

DN 135:335112

ΤI Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

SO PCT Int. Appl., 92 pp. CODEN: PIXXD2

```
IN
     Chancellor, Michael B.; Huard, Johnny; Capelli, Christopher C.;
AΒ
     The present invention provides muscle-derived progenitor cells that show
     long-term survival following transplantation into body tissues and which
     can augment soft tissue following introduction (e.g. via injection,
     transplantation, or implantation) into a site of soft tissue. Also
     provided are methods of isolating muscle-derived progenitor cells, and
     methods of genetically modifying the cells for gene transfer therapy.
     invention further provides methods of using compns. comprising
     muscle-derived progenitor cells for the augmentation and bulking of
     mammalian, including human, soft tissues in the treatment of various
     cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention
     provides treatments and amelioration for dermatol. conditions,
     gastroesophageal reflux, vesico-ureteral reflux, urinary
     incontinence, fecal incontinence, heart failure, and myocardial
     infarction.
     PATENT NO.
                           KIND
                                  DATE
                                               APPLICATION NO.
                                                                        DATE
      ----
                                  _____
                                               -----
                                  20011025
     WO 2001078754
                           A2
                                              WO 2001-US12084
                                                                        20010412
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
              HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
              RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
            VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                           A2 20030108 EP 2001-924998
     EP 1272204
                                                                        20010412
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003531125
                           T2
                                  20031021
                                            JP 2001-576054
                                                                        20010412
=> d an ti so au ab pi 113 2
L13
     ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     1998:542993 CAPLUS
DN
     129:157327
     Treatment for urinary incontinence using gene
ΤI
     therapy techniques
SO
     PCT Int. Appl., 118 pp.
     CODEN: PIXXD2
IN
     Coleman, Michael
AB
     The invention is directed in part towards methods of treating
     urinary incontinence using gene
     therapy techniques. The methods provide for the delivery and
     expression of growth factors or neurotrophic factors in mammalian tissues.
     PATENT NO.
                          KIND
                                 DATE
                                              APPLICATION NO.
                                                                  DATE
                          _ _ _ _
ΡI
     WO 9833529
                           A1
                                  19980806
                                              WO 1998-US2051
                                                                       19980204 <--
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
     AU 9861427
                           Α1
                                  19980825
                                               AU 1998-61427
                                                                       19980204 <--
     AU 739224
                           B2
                                  20011004
     EP 981378
                           A1
                                  20000301
                                              EP 1998-906110
                                                                       19980204
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

IE, FI

T2

20010807

JP 2001511154

JP 1998-533206

19980204

L Number	Hits	Search Text	DB	Time stamp
3	601	urinary NEAR incontinence NEAR stress	USPAT;	2004/09/09 11:14
			US-PGPUB;	
			EPO; JPO;	
			DERWENT;	
4	482	(urinary NEAR incontinence NEAR stress)	USOCR USPAT;	2004/09/09 11:03
1	402	and (urethra OR sphincter)	US-PGPUB;	2001/03/03 II:03
		and (droined on opiniosor)	EPO; JPO;	
			DERWENT;	
			USOCR	
5	7	((az inaz) nizm. zmoonezmenee nizm. oezebb)	USPAT;	2004/09/09 11:13
		and (urethra OR sphincter)) and	US-PGPUB;	
	·	myoblast\$1	EPO; JPO; DERWENT;	
			USOCR .	
6	383	((urinary NEAR incontinence NEAR stress)	USPAT;	2004/09/09 11:05
		and (urethra OR sphincter)) and (muscle	US-PGPUB;	
		OR myoblast\$1)	EPO; JPO;	
			DERWENT;	
7	070	///winew. NEAD incentions NEAD	USOCR	0004/00/00 11 15
'	279	(((urinary NEAR incontinence NEAR stress) and (urethra OR sphincter)) and (muscle	USPAT;	2004/09/09 11:06
		OR myoblast\$1)) and (transplant\$4 OR	US-PGPUB; EPO; JPO;	•
		inject\$4 or implant\$4)	DERWENT;	
		1	USOCR	
8	46	((((urinary NEAR incontinence NEAR stress)	USPAT;	2004/09/09 11:07
		and (urethra OR sphincter)) and (muscle	US-PGPUB;	
		OR myoblast\$1)) and (transplant\$4 OR	EPO; JPO;	
		inject\$4 or implant\$4)) and 424/\$\$.ccls.	DERWENT;	
10	8	(stress NEAR urinary NEAR incontinence)	USOCR USPAT;	2004/09/09 11:12
	o	and myoblast	US-PGPUB;	4004/03/03 11:12
		and mjobzabo	EPO; JPO;	
			DERWENT;	
			USOCR	
11	1072	urinary NEAR incontinence.clm.	USPAT;	2004/09/09 11:13
			US-PGPUB;	
			EPO; JPO; DERWENT;	
			USOCR USOCR	
13	2	(urinary NEAR incontinence.clm.) and	USPAT;	2004/09/09 11:13
		myoblast\$1.clm.	US-PGPUB;	
			EPO; JPO;	
			DERWENT;	
14	16	(urinary NEAR incontinence NEAR stress)	USOCR USPAT;	2004/00/00 11:15
	10	and (gene ADJ therapy)	USPAT; US-PGPUB;	2004/09/09 11:15
		(5 5.00±ap _f)	EPO; JPO;	
			DERWENT;	
			USOCR	
15	7	CHANCELLOR NEAR MICHAEL	USPAT;	2004/09/09 11:16
]			US-PGPUB;	
			EPO; JPO; DERWENT;	
			USOCR	
-	7	(US-5763416-\$ or US-5942496-\$ or	USPAT;	2002/05/15 17:14
		US-6239117 - \$ or US-6271211-\$).did. or	EPO;	,,
		(WO-9833529-\$).did. or (US-6239117-\$ or	DERWENT	
		WO-200037124-\$ or US-20010041355-\$).did.		
-	10	(US-5942496-\$ or US-5763416-\$ or	USPAT;	2002/05/16 14:20
	İ	US-6271211-\$ or US-6239117-\$ or US-5068224-\$ or US-5444047-\$).did. or	EPO;	
ŀ		(WO-9833529-\$ or WO-9824922-\$).did. or	DERWENT	
		(US-20010041355-\$ or US-6239117-\$ or]
		WO-200037124-\$).did.		
-	157	(IGF-I or IGF-II or (insulin ADJ like))	USPAT;	2002/05/16 14:23
1		and (URETHERA\$1 OR SPHINCTER OR DETRUSOR	US-PGPUB;	
		OR PELVIC)	EPO; JPO;	
			DERWENT;	
			USOCR	

33 ([IGF-I or IGF-II or SPHINTER OR DETRUSOR OR PERFORM OR PER		,			
OR PELVIC) and ((atrophy or atrophicd or dysfunction) SAME (muscle or muscular)) USOR USPAT: USPAC: USPAT: U	_	33	(, ,	USPAT;	2002/05/16 14:26
3691 3691			l '	1	
Same Same (muscle or muscular) USSCR USPAT; USP					
Separate				1	
-	_	3691			2004/01/22 12:23
Company ADJ incontinence		3031	diffially Abo incontinence		2004/01/22 12:25
DERWENT; USCAR Uscape				1	
2					
ADJ nitric ADJ oxide)					
- 4229 urinary WITH incontinence USPAT; USCACR USPAT; US-PGPUB; EPG; JPG; DERWENT; USCCR USPAT; US-PGPUB; EPG; JPG; DERWENT; USCCR USPAT; USCACR US-5444047-5 or US-5466676-\$ or US-6271211-\$ or US-568986-3, did. or US-933529-\$ or US-6231917-\$ or WO-200037124-5 or US-6231917-\$ or WO-20037124-5 or US-6231917-\$ or US-6447768-\$ or US-6231917-\$ or US-658865-3, did. or (WO-9833529-\$ or WO-9924922-\$ or WO-9956785-\$ or US-6231917-\$ or US-658986-3, did. - 5 ((US-5942496-\$ or US-5763416-\$ or US-623917-\$ or US-623917-\$ or US-6447768-\$ or US-623917-\$ or US-6456676-\$ or US-6721211-\$ or US-6133281-\$, did. or (WO-9833529-\$ or US-6447768-\$ or US-623917-\$ or WO-200037124-\$ or US-658956-3, did.) or US-623917-\$ or US-645776-\$ or US-623917-\$ or WO-200037124-\$ or US-658956-3, did.) or US-623917-\$ or US-645768-\$ or US-658956-3, did.) or US-20010041355-\$ or US-658956-3, did.) or US-20010041355-\$ or US-66978-\$ or WO-9956785-\$ or US-658956-3, did.) or US-20010041355-\$ or US-67908-\$ or WO-9956785-\$ or US-658956-3, did.) or US-20010041355-\$ or US-67908-\$ or WO-9956785-\$ or WO-9956785-\$ or US-66978-\$ or WO-9956785-\$ or US-66978-\$ or WO-9956785-\$ or US-66978-\$ or WO-9956785-\$ or US-66978-\$ or WO-995678-\$ or WO-995678-\$ or WO-995678-\$ or WO-995678-\$ or US-64978-\$ or WO-995678-\$ or WO-9	_	2	(urinary ADJ incontinence) and (inducible	USPAT;	2002/10/09 18:09
- 4229 urinary WITH incontinence			ADJ nitric ADJ oxide)	US-PGPUB;	
- 4229 urinary WITH incontinence USPAT; USPACPUB; EFC; JPO; DERWENT; USPAC					
- 4229 urinary WITH incontinence - 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide) - 507 inducible ADJ nitric ADJ oxide - 507 inducible ADJ nitric ADJ oxide - 75 (inducible ADJ nitric ADJ oxide) - 76 (US-5942496-\$ or US-5763416-\$ or US-PERMENT) - 16 (US-5942496-\$ or US-5763416-\$ or US-PERMENT) - 17 (US-5942496-\$ or US-5763416-\$ or US-PERMENT) - 18 (US-5942496-\$ or US-647768-\$ or US-763416-\$ or US-763313-\$ or US-6487768-\$ or US-623317-\$ or WO-980306-\$ or US-623317-\$ or US-763416-\$ or US-2010014135-\$ or US-623317-\$ or US-6487768-\$ or US-6487768-\$ or US-65856-\$ or US-6271211-\$ or US-763313-\$ or US-6487768-\$ or US-633312-\$ or US-56487768-\$ or US-623317-\$ or WO-98037124-\$ or US-763311-\$ or US-76331					
- 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide) - 507 inducible ADJ nitric ADJ oxide - 75 (inducible ADJ nitric ADJ oxide) - 76 (inducible ADJ nitric ADJ oxide) - 77 (inducible ADJ nitric ADJ oxide) - 86 (US-5942496-\$ or US-5763416-\$ or US-EPO; JPO; DERMENT; USCAR USPAT; US-PGPUB; EPO; JPO; DERMENT; USCAR USPAT; US-PGPUB; EPO; JPO; DERMENT; USCAR USSAT; US-539113-\$ or US-5447047-\$ or US-5086224-\$ or US-5744047-\$ or US-5086224-\$ or US-5744047-\$ or US-5086224-\$ or US-5744047-\$ or US-5086224-\$ or US-5763416-\$ or US-6239117-\$ or WO-090037124-\$ or US-568555-\$),did. - 76 (US-5942496-\$ or US-5763416-\$ or US-6239117-\$ or WO-09037124-\$ or US-568555-\$),did. - 86 (US-5942496-\$ or US-5763416-\$ or US-6239117-\$ or WO-09037124-\$ or US-568255-\$),did. - 97 (US-5942496-\$ or US-5763416-\$ or US-5633528-\$ or WO-9860906-\$),did. or (US-20010041355-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-569555-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-563955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-56955-\$),did.) - 18 (US-5942496-\$ or US-5763416-\$ or US-56955-\$),did. - 18 (US-5942496-\$ or US-5763416-\$ or US-56955-\$),did. - 18 (US-5942496-\$ or US-5763416-\$ or US-569555-\$),did. - 18 (US-594249-\$ or WO-985785-\$ or WO-9862995-\$),did. - 18 (US-594249-\$ or WO-985785-\$ or WO-9862995-\$),did. - 18 (US-594249-\$) or WO-985785-\$ or WO-9862995-\$ - 18 (US-594249-\$) or WO-985785-\$ or WO-9862995-\$ - 18 (US-594249-\$) or					
- 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide)	-	4229	urinary WITH incontinence		2002/10/09 17:59
- 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide) - 507 inducible ADJ nitric ADJ oxide - 507 inducible ADJ nitric ADJ oxide - 75 (inducible ADJ nitric ADJ oxide) - 76 (inducible ADJ nitric ADJ oxide) - 77 (inducible ADJ nitric ADJ oxide) - 78 (inducible ADJ nitric ADJ oxide) - 8 (US-5942496-\$ or US-5763416-\$ or US-67 US-5466676-\$ or US-6771211-\$ or US-508224-\$ or US-6771211-\$ or US-6739113-\$ or US-6440477-\$ or US-6739113-\$ or US-6440477-\$ or US-6739113-\$ or US-6440475-\$ or US-6739113-\$ or US-6440475-\$ or US-6239117-\$ or WO-20037124-\$ or US-6239117-\$ or WO-20037124-\$ or US-6133281-\$).did. or (US-2010041355-\$ or US-6133281-\$).did. or (US-2010041355-\$ or US-6133281-\$).did. or (WO-9833529-\$ or US-6133281-\$).did. or (WO-9833529-					
- 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide) - 507 inducible ADJ nitric ADJ oxide - 507 inducible ADJ nitric ADJ oxide - 75 (inducible ADJ nitric ADJ oxide) - 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (US-5942496-\$ or US-5763416-\$ or US-5666676-\$ or US-6271211-\$ or US-5666676-\$ or US-6271211-\$ or US-5068224-\$ or US-6133281-\$ or US-633291-\$ or US-633291-\$ or US-633291-\$ or US-633291-\$ or US-658565-\$ or US-6271211-\$ or US-5686676-\$ or US-6271211-\$ or US-568265-\$ or US-6133281-\$ or US-644768-\$ or US-6133281-\$ or US-644768-\$ or US-6133281-\$ or US-644768-\$ or US-6133281-\$ or US-6133281-\$ or US-644768-\$ or US-6133281-\$ or					
- 6 (urinary WITH incontinence) and (inducible ADJ nitric ADJ oxide) - 507 inducible ADJ nitric ADJ oxide - 507 inducible ADJ nitric ADJ oxide - 75 (inducible ADJ nitric ADJ oxide) - 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (U8-5942496-\$ or US-5763416-\$ or US-67000000000000000000000000000000000000				I	
Comparison Com	l _	6	(urinary WITH incontingno) and		2002/10/09 17.59
- 507 inducible ADJ nitric ADJ oxide				1	2002/10/09 1/:59
- 507 inducible ADJ nitric ADJ oxide USPAT; US-PGPUB; EPO_JPO_DERWENT; US-PGPUB; EPO_JPO_DERWENT; US-PGPUB; EPO_JPO_DERWENT; USCAR US-5466676-\$ or US-5763416-\$ or US-5769113-\$ or US-57995678-\$ or US-529917-\$ or WO-9820492-\$ or WO-9956785-\$ or US-529917-\$ or WO-982092-\$ or WO-9956785-\$ or US-529917-\$ or WO-982092-\$ or WO-9956785-\$ or US-529917-\$ or WO-982092-\$ or WO-9956785-\$ or US-5769113-\$ or U			(110001010 1100 HIGHE ADD OXIGE)	1	
- 507 inducible ADJ nitric ADJ oxide USPAT; US-PGPUB; EPO; JPO; DERMENT; USOCR US-5466676-\$ or US-5763416-\$ or US-5466676-\$ or US-5763416-\$ or US-57668224-\$ or US-5440407-\$ or US-5739113-\$ or US-5440407-\$ or US-5339117-\$ or WO-9803529-\$ or WO-960006-\$). did. or (WO-9833529-\$ or US-55658-\$). did. - 5 (US-5942496-\$ or US-5763416-\$ or US-5739113-\$ or US-5466678-\$ or US-544047-\$ or US-5739113-\$ or US-644768-\$ or US-52010041355-\$ or US-56585-\$). did. - 5 (US-5942496-\$ or US-5763416-\$ or US-56585-\$). did. or (WO-9833529-\$ or WO-98608224-\$ or WO-996082-\$ or WO-9960906-\$). did. or (WO-9833529-\$ or WO-960006-\$). did. or (WO				1	
- 507 inducible ADJ nitric ADJ oxide USPAT; USPAT; USCR US-5068224 % or US-5444047-% or US-5739113-% or US-6447768-% or US-613281-%).did. or (WO-9839529-% or WO-9800006-%).did. or (WS-20010041355-% or US-6239117-% or WO-200037124-% or US-568565-%).did. (US-5942496-% or US-5644768-% or US-5686224 % or US-5644768-% or US-5686244 % or US-5444047-% or US-5068224 % or US-5444047-% or US-5133281-%).did. or (WO-9839529-% or US-6133281-%).did. or (WO-9839529-% or US-6133281-%).did. or (WS-9839529-% or US-668565-%).did. or (WS-20010041355-% or US-6239117-% or WO-9956785-% or US-6258565-%).did.) and (inducible ADJ nitric ADJ oxide ADJ nitric ADJ oxide ADJ synthase SAME (gene ADJ therapy) US-FOPUB; EPO; JPO; DERWENT; USCR USPAT; USCR USPAT				1	
- 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (US-5942496-\$ or US-5763416-\$ or US-5CPUB; EPO; JPO; DERWENT; USOCR US-5466676-\$ or US-5271211-\$ or US-5066224-\$ or US-5444047-\$ or US-5739113-\$ or US-613321-\$), did, or (WO-9933529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-558565-\$), did 17 (US-5942496-\$ or US-5763416-\$ or US-506823117-\$ or WO-900006-\$), did, or (US-20010041355-\$ or US-568565-\$) did 18 (US-5942496-\$ or US-5763416-\$ or US-568565-\$), did 19 (US-5942496-\$ or US-5763416-\$ or US-5686676-\$ or US-6271211-\$ or US-5686676-\$ or US-6271211-\$ or US-506824-\$ or US-5444047-8 or US-568565-\$), did. or (WO-993529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9824922-\$ or WO-9956785-\$ or US-568565-\$), did.) and (inducible ADJ nitric ADJ oxide ADJ synthase) - 443 and (inducible ADJ nitric ADJ oxide ADJ synthase) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) - 20 (inducible ADJ nitric ADJ oxide ADJ synthas	-	507	inducible ADJ nitric ADJ oxide	1	2002/10/09 18:09
- 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (US-5942496-\$ or US-5763416-\$ or US-FGPUB; EPO; JPO; DERMENT; US-5068224-\$ or US-5440477-\$ or US-5139113-\$ or US-6447768-\$ or US-5739113-\$ or US-6447768-\$ or US-6271211-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-995785-\$ or US-5271211-\$ or US-5658565-\$).did. or (WO-9000741355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5739113-\$ or US-5444077-\$ or US-5739113-\$ or US-544407-\$ or US-5739113-\$ or US-544407-\$ or US-5739113-\$ or US-544407-\$ or US-5739113-\$ or US-544407-\$ or US-5739113-\$ or US-6447768-\$ or US-68224-\$ or US-544407-\$ or US-5739113-\$ or US-6447768-\$ or US-6239117-\$ or WO-9800006-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-995785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-20037124-\$ or US-6239117-\$ or WO				US-PGPUB;	
- 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (US-5942496-\$ or US-5763416-\$ or US-A66676-\$ or US-6271211-\$ or US-5366676-\$ or US-6271211-\$ or US-5346676-\$ or US-644047-\$ or US-6133281-\$).did. or (W0-9833529-\$ or W0-9600006-\$).did. or (US-20010041355-\$ or US-568224-\$ or US-5763416-\$ or US-558565-\$).did. - 17 (US-5942496-\$ or US-5763416-\$ or US-6239117-\$ or W0-900037124-\$ or US-558667-\$ or US-6271211-\$ or US-5668224-\$ or US-5763416-\$ or US-5668224-\$ or US-5763416-\$ or US-5668224-\$ or US-5763416-\$ or US-5068224-\$ or US-5644768-\$ or US-6133281-\$).did. or (W0-9833529-\$ or W0-9924922-\$ or W0-9956785-\$ or US-6133281-\$).did. or (W0-9833529-\$ or US-6133281-\$).did. or (W0-9833529-\$ or US-6133281-\$).did. or (W0-9833529-\$ or US-6239117-\$ or W0-900037124-\$ or US-6239117-\$ or W0-900037124-\$ or US-6239117-\$ or W0-200037124-\$ or US-623911		1			
- 75 (inducible ADJ nitric ADJ oxide) and (gene ADJ therapy) - 16 (US-5942496-\$ or US-5763416-\$ or US-CRPUB; EPO; JPO; US-CRP				DERWENT;	
Gene ADJ therapy)					
- 16 (US-5942496-\$ or US-5763416-\$ or US-5068224-\$ or US-5444047-\$ or US-5068224-\$ or US-5444047-\$ or US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-56239117-\$ or WO-2000041355-\$ or US-56239117-\$ or WO-200037124-\$ or US-5466676-\$ or US-5658565-\$).did. - 5 ((US-5942496-\$ or US-5763416-\$ or US-5668224-\$ or US-5763416-\$ or US-5668224-\$ or US-5763416-\$ or US-56133281-\$).did. or (WO-9833529-\$ or WO-9956785-\$ or US-5466676-\$ or US-5763416-\$ or US-56133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9824925-\$ or WO-9823922-\$ or WO-9956785-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9600006-\$).did. or (WO-9833529-\$ or WO-9600006-\$).did. or (WO-9833529-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-658565-\$).did.) and (inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)	-	75		· ·	2002/10/09 18:10
- 16 (US-5942496-\$ or US-5763416-\$ or US-5466676-\$ or US-6271211-\$ or US-5466676-\$ or US-6271211-\$ or US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9933529-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-20037124-\$ or US-5688565-\$).did. - 5 ((US-5942496-\$ or US-5763416-\$ or US-6239117-\$ or WO-9624922-\$ or WO-9666676-\$ or US-6447768-\$ or US-568865-\$).did. or (US-20010041355-\$ or US-568224-\$ or US-5763416-\$ or US-739113-\$ or US-6447768-\$ or US-5739113-\$ or US-6447768-\$ or US-5739113-\$ or US-6447768-\$ or US-6239117-\$ or WO-99356785-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-960006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-20037124-\$ or US-568865-\$).did.) and (inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)			(gene ADJ therapy)	1	
- 16 (US-5942496-\$ or US-5763416-\$ or US-566676-\$ or US-5271211-\$ or US-5666224-\$ or US-5444047-\$ or US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or US-6239117-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-5588565-\$).did. - 15 (US-5942496-\$ or US-5763416-\$ or US-688224-\$ or US-5763416-\$ or US-568824-\$ or US-544047768-\$ or US-568224-\$ or US-544047768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-982492-\$ or WO-9956785-\$ or US-633281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ oxide ADJ synthase) SAME (muscle ADJ ceil) US-PGPUB; EPO; JPO; DERWENT; US-PGPUB; EPO; JPO; DERWENT; US-PGPUB; EPO; JPO; DERWENT; US-PGPUB; EPO; JPO; DERWENT;					
- 16 (US-5942496-\$ or US-5763416-\$ or US-5763416-\$ or US-546676-\$ or US-5744047-\$ or US-5068224-\$ or US-5444047-\$ or US-5739113-\$ or US-6447768-\$ or WO-9824922-\$ or WO-9933529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-5639117-\$ or US-568565-\$).did. or (US-20010041355-\$ or US-568565-\$).did. or US-573416-\$ or US-568565-\$).did. or US-573416-\$ or US-568565-\$).did. or US-573416-\$ or US-568566-\$).did. or US-573416-\$ or US-568224-\$ or US-57763416-\$ or US-5068224-\$ or US-5671211-\$ or US-568224-\$ or US-647768-\$ or US-613281-\$).did. or (WO-9833529-\$ or WO-9800006-\$).did. or (WO-9833529-\$ or US-613281-\$).did. or (WO-9833529-\$ or US-613281-\$).did. or (WO-9833529-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-200037124-\$ or US-568565-\$).did.) and (inducible ADJ nitric ADJ oxide ADJ synthase				1	
US-5466676-\$ or US-6271211-\$ or US-5068224-\$ or US-5444047-\$ or US-5739113-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-568565-\$).did. ((US-5942496-\$ or US-5763416-\$ or US-566824-\$ or US-5763416-\$ or US-506824-\$ or US-6271211-\$ or US-506824-\$ or US-5440407-\$ or US-5739113-\$ or US-6447768-\$ or US-613281-\$).did. or (WO-9833529-\$ or WO-9800006-\$).did. or (US-20010041355-\$ or US-633127-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-633117-\$ or WO-200037124-\$ or US-658565-\$).did.) and (inducible ADJ nitric ADJ oxide ADJ nitric ADJ oxide ADJ synthase) - 443	_	16	/US-5942496-5 or US-5763416-5 or		2002/10/00 10-15
US-5068224-\$ or US-5444047-\$ or US-5733113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-62393117-\$ or WO-200037124-\$ or US-5239117-\$ or WO-200037124-\$ or US-568565-\$).did. 5 ((US-5942496-\$ or US-5763416-\$ or US-5763416-\$ or US-5739113-\$ or US-6447768-\$ or US-5739113-\$ or US-6447768-\$ or US-5133281-\$).did. or (WO-9933529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (WS-20010041355-\$ or US-5239117-\$ or WO-200037124-\$ or US-5339117-\$ or WO-200037124-\$ or US-633281-\$).did. or (WO-9933529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9824922-\$ or WO-9956785-\$ or US-5239117-\$ or WO-200037124-\$ or US-539117-\$ or WO-200037124-\$ or US-633281-\$ or US-633281-\$ or US-633281-\$ or US-6347768-\$ or US-639117-\$ or WO-200037124-\$ or US-639117-\$ or WO-200037124-\$ or US-647768-\$ or US-639117-\$ or WO-200037124-\$ or US-647768-\$ or US-639117-\$ or WO-200037124-\$ or US-960006-\$ \) .did. or (WO-9933529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-PGPUB; EPO; JPO; DERWENT; US-PGPUB; EPO; JPO; DERWENT; US-PGPUB; EPO; JPO; DERWENT; USOCR US-77; US-78908; EPO; JPO; DERWENT; US-78908; EPO; JPO; DERWENT; US-78908; EPO; JPO; DERWENT; US-78908; EPO; JPO; DERWENT;		10			2002/10/09 18:13
US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did. US-5468676-\$ or US-671211-\$ or US-568824-\$ or US-5444047-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-62008-\$ or US-6239117-\$ or WO-200037124-\$ or US-62008-\$ or US-6239117-\$ or WO-200037124-\$ or US-62008-\$ or					
US-6133281-\$).did. or (WO-9833529-\$ or WO-9800006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-568565-\$).did. (US-5942496-\$ or US-5763416-\$ or US-576346676-\$ or US-5466676-\$ or US-5444047-\$ or US-5068224-\$ or US-5444047-\$ or US-513281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-613281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)	ļ			DEKWENT	
WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did. S (US-5942496-\$ or US-5763416-\$ or US-PGPUB; US-5068224-\$ or US-6447078-\$ or US-5739113-\$ or US-6447078-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-200037124-\$ or US-658565-\$).did.) and (inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 20 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)					•
US-6239117-\$ or WO-200037124-\$ or US-5658865-\$).did. 5 (US-5942496-\$ or US-5763416-\$ or US-5068224-\$ or US-6271211-\$ or US-5068224-\$ or US-644077-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6588565-\$).did. or (WS-20010041355-\$ or US-6588565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 443 inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 2002/10/17 18:49 2002/10/17 18:56			WO-9824922-\$ or WO-9956785-\$ or		
US-5658565-\$).did. ((US-5942496-\$ or US-5763416-\$ or US-PGPUB; US-5466676-\$ or US-6271211-\$ or US-5068224-\$ or US-5444047-\$ or US-5068224-\$ or US-5444047-\$ or US-6733281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) and (inducible ADJ synthase) 443 inducible ADJ nitric ADJ oxide ADJ synthase) 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 2002/10/17 18:16 2002/10/17 18:49 2002/10/17 18:56					
S				,	
US-5466676-\$ or US-6271211-\$ or US-5068224-\$ or US-5444047-\$ or US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) and (inducible ADJ synthase) 443 inducible ADJ nitric ADJ oxide ADJ synthase) 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)		_			
US-5068224-\$ or US-5444047-\$ or US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 443 inducible ADJ nitric ADJ oxide ADJ synthase) 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)	-	5			2002/10/09 18:16
US-5739113-\$ or US-6447768-\$ or US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or US-6239117-\$ or WO-200037124-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ cell) 2002/10/17 18:56					
US-6133281-\$).did. or (WO-9833529-\$ or WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell)			· · · · · · · · · · · · · · · · ·		
WO-9824922-\$ or WO-9956785-\$ or WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase - 443 inducible ADJ nitric ADJ oxide ADJ synthase - 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) - 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)				DEWMENT	
WO-9600006-\$).did. or (US-20010041355-\$ or US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 48 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)					
US-6239117-\$ or WO-200037124-\$ or US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) 443 inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell)					
US-5658565-\$).did.) and (inducible ADJ nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 26 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell)					
nitric ADJ oxide) inducible ADJ nitric ADJ oxide ADJ synthase 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 2002/10/17 18:49 2002/10/17 18:49 2002/10/17 18:49					
synthase 7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 2002/10/17 19:00 2002/10/17 19:00 2002/10/17 19:00			nitric ADJ oxide)		
To dinducible ADJ nitric ADJ oxide ADJ Synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ Synthase) SAME (muscle ADJ cell) EPO; JPO; DERWENT; USOCR USPAT;	-	443		USPAT;	2002/10/17 18:49
To discript and the synthase) SAME (gene ADJ oxide ADJ o			synthase	· ·	
To (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 2002/10/17 18:56 2002/10/17 19:00 2002/10/17 19:00 2002/10/17 19:00					
7 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (gene ADJ therapy) 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 27 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 28 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) 29 (2002/10/17 18:56 US-PGPUB; EPO; JPO; DERWENT;					
synthase) SAME (gene ADJ therapy) US-PGPUB; EPO; JPO; DERWENT; USOCR USPAT; US-PGPUB; Synthase) SAME (muscle ADJ cell) US-PGPUB; EPO; JPO; DERWENT; DERWENT;	_	7	(inducible ADI nitric ADI coide ADI		2002/10/17 10 50
EPO; JPO; DERWENT; USOCR USPAT; Synthase) SAME (muscle ADJ cell) US-PGPUB; EPO; JPO; DERWENT;		'		·	2002/10/1/ 18:56
DERWENT; USOCR USPAT; USPAT; USPAT; USPAT; US-PGPUB; EPO; JPO; DERWENT;			symmage, pure (dene upo fuetaba)	· ·	
- 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) USOCR USPAT; US-PGPUB; EPO; JPO; DERWENT;					
- 26 (inducible ADJ nitric ADJ oxide ADJ synthase) SAME (muscle ADJ cell) USPAT; US-PGPUB; EPO; JPO; DERWENT;					
synthase) SAME (muscle ADJ cell) US-PGPUB; EPO; JPO; DERWENT;	-	26	(inducible ADJ nitric ADJ oxide ADJ		2002/10/17 19:00
EPO; JPO; DERWENT;					
				EPO; JPO;	
USOCR					
				USOCR	

	1	I /industrial and situate and and	Tropam.	1 2002 /10 /17 10 02
-	1	(inducible ADJ nitric ADJ oxide ADJ	USPAT;	2002/10/17 19:03
		synthase) SAME (myoblast)	US-PGPUB;	
			EPO; JPO;	
			DERWENT;	
	626		USOCR	
-	636	stress NEAR urinary NEAR incontinence	USPAT;	2004/01/22 13:06
			US-PGPUB;	
			EPO; JPO;	
			DERWENT;	l i
			USOCR	ļ i
-	3	(stress NEAR urinary NEAR incontinence)	USPAT;	2004/01/22 13:06
		and muscle-derived	US-PGPUB;	
			EPO; JPO;	
11			DERWENT;	
			USOCR	
-	12	1 (USPAT;	2004/01/22 13:07
		and (gene NEAR therapy)	US-PGPUB;	
			EPO; JPO;	
			DERWENT;	
			USOCR	
-	28	(US-6271211-\$ or US-5942496-\$ or	USPAT;	2004/01/22 13:08
		US-5763416-\$ or US-5068224-\$ or	US-PGPUB;	
		US-5444047-\$ or US-5739113-\$ or	EPO;	
		US-5466676-\$ or US-6133281-\$ or	DERWENT	
		US-6447768-\$ or US-5658565-\$ or		
		US-5594032-\$ or US-5882908-\$ or		
		US-5468630-\$).did. or (US-20020155096-\$ or		
		US-20030104455-\$ or US-20030148394-\$).did.		
		or (WO-9833529-\$ or WO-9824922-\$ or		
		WO-9956785-\$ or WO-9600006-\$).did. or		·
		(US-6239117-\$ or US-20010041355-\$ or		
		WO-200037124-\$ or WO-200078946-\$ or		
		US-5594032-\$ or WO-9956785-\$ or		
		WO-2003061573-\$ or WO-2003039475-\$).did.		
	L			L !